AR058173A1 - Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas - Google Patents
Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicasInfo
- Publication number
- AR058173A1 AR058173A1 ARP060104776A ARP060104776A AR058173A1 AR 058173 A1 AR058173 A1 AR 058173A1 AR P060104776 A ARP060104776 A AR P060104776A AR P060104776 A ARP060104776 A AR P060104776A AR 058173 A1 AR058173 A1 AR 058173A1
- Authority
- AR
- Argentina
- Prior art keywords
- sdf
- prevention
- treatment
- neurological diseases
- neurological
- Prior art date
Links
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 title abstract 3
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05110206 | 2005-10-31 | ||
| US73414205P | 2005-11-07 | 2005-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058173A1 true AR058173A1 (es) | 2008-01-23 |
Family
ID=35967039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104776A AR058173A1 (es) | 2005-10-31 | 2006-10-31 | Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080253996A1 (enExample) |
| EP (1) | EP1942940A2 (enExample) |
| JP (1) | JP2009513689A (enExample) |
| KR (1) | KR20080060226A (enExample) |
| CN (1) | CN101300031A (enExample) |
| AR (1) | AR058173A1 (enExample) |
| AU (1) | AU2006310577B2 (enExample) |
| BR (1) | BRPI0617823A2 (enExample) |
| CA (1) | CA2617598A1 (enExample) |
| EA (1) | EA015716B1 (enExample) |
| NZ (1) | NZ565639A (enExample) |
| UA (1) | UA96926C2 (enExample) |
| WO (1) | WO2007051785A2 (enExample) |
| ZA (1) | ZA200800981B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7696309B2 (en) | 2006-10-23 | 2010-04-13 | The Brigham And Women's Hospital, Inc. | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| WO2011106234A1 (en) * | 2010-02-25 | 2011-09-01 | Provasculon, Inc. | Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| US9249204B2 (en) * | 2011-06-01 | 2016-02-02 | Jyant Technologies, Inc. | Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
| JP6145089B2 (ja) * | 2011-06-07 | 2017-06-07 | メソブラスト インターナショナル エスエイアールエル | ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法 |
| US11419916B2 (en) * | 2012-09-11 | 2022-08-23 | Energesis Pharmaceuticals, Inc. | Methods and compositions for inducing differentiation of human brown adipocyte progenitors |
| US9797910B2 (en) | 2013-06-19 | 2017-10-24 | Merck Sharp & Dohme Corp. | Assay for determining endogenous levels of analyte in vivo |
| EP3191991B1 (en) * | 2014-09-10 | 2021-01-13 | Koninklijke Philips N.V. | Image report annotation identification |
| ITUA20161364A1 (it) | 2016-03-04 | 2017-09-04 | Antonino Cattaneo | Inibitore di tnf alpha astrocitario per l’uso nel trattamento di malattie neurologiche. |
| US20180222957A1 (en) * | 2017-02-03 | 2018-08-09 | Vicapsys, Inc. | Modified cxcl12 polypeptides and uses thereof |
| CN107325187B (zh) * | 2017-07-19 | 2021-11-09 | 黄子为 | 一种具有cxcr4蛋白激动活性的多肽及其应用和药物组合物 |
| US11553871B2 (en) | 2019-06-04 | 2023-01-17 | Lab NINE, Inc. | System and apparatus for non-invasive measurement of transcranial electrical signals, and method of calibrating and/or using same for various applications |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1235692A (en) | 1991-01-18 | 1992-08-27 | Synergen, Inc. | Methods for treating tumor necrosis factor mediated diseases |
| CA2117953C (en) * | 1993-10-14 | 2001-12-11 | Tasuku Honjo | Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same |
| JP2002506830A (ja) * | 1998-03-13 | 2002-03-05 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 治療的ケモカイン受容体アンタゴニスト |
| CA2245224A1 (en) * | 1998-08-14 | 2000-02-14 | Jiang-Hong Giong | Chemokine receptor antagonists and chemotherapeutics |
| US7157418B1 (en) * | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| DE10027383A1 (de) * | 2000-06-02 | 2001-12-20 | Rhein Biotech Proz & Prod Gmbh | Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz |
| US20040037811A1 (en) * | 2002-08-22 | 2004-02-26 | The Cleveland Clinic Foundation | Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy |
| EP1493438A1 (en) * | 2003-07-03 | 2005-01-05 | Bayer HealthCare AG | Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states |
| JP5026083B2 (ja) * | 2003-10-31 | 2012-09-12 | クロンズ ホールディングズ カンパニー リミテッド | 神経再生ペプチド及び脳損傷治療におけるそれらの使用方法 |
-
2006
- 2006-10-30 WO PCT/EP2006/067949 patent/WO2007051785A2/en not_active Ceased
- 2006-10-30 AU AU2006310577A patent/AU2006310577B2/en not_active Ceased
- 2006-10-30 CA CA002617598A patent/CA2617598A1/en not_active Abandoned
- 2006-10-30 EP EP06807673A patent/EP1942940A2/en not_active Ceased
- 2006-10-30 KR KR1020087007031A patent/KR20080060226A/ko not_active Ceased
- 2006-10-30 ZA ZA200800981A patent/ZA200800981B/xx unknown
- 2006-10-30 BR BRPI0617823-5A patent/BRPI0617823A2/pt not_active IP Right Cessation
- 2006-10-30 UA UAA200802964A patent/UA96926C2/ru unknown
- 2006-10-30 EA EA200801244A patent/EA015716B1/ru not_active IP Right Cessation
- 2006-10-30 NZ NZ565639A patent/NZ565639A/en not_active IP Right Cessation
- 2006-10-30 JP JP2008538353A patent/JP2009513689A/ja active Pending
- 2006-10-30 CN CNA2006800404916A patent/CN101300031A/zh active Pending
- 2006-10-30 US US12/067,224 patent/US20080253996A1/en not_active Abandoned
- 2006-10-31 AR ARP060104776A patent/AR058173A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200800981B (en) | 2009-04-29 |
| NZ565639A (en) | 2012-03-30 |
| CN101300031A (zh) | 2008-11-05 |
| WO2007051785A3 (en) | 2007-09-07 |
| US20080253996A1 (en) | 2008-10-16 |
| UA96926C2 (ru) | 2011-12-26 |
| WO2007051785A2 (en) | 2007-05-10 |
| CA2617598A1 (en) | 2007-05-10 |
| EA015716B1 (ru) | 2011-10-31 |
| EA200801244A1 (ru) | 2009-02-27 |
| JP2009513689A (ja) | 2009-04-02 |
| AU2006310577A1 (en) | 2007-05-10 |
| EP1942940A2 (en) | 2008-07-16 |
| BRPI0617823A2 (pt) | 2011-08-09 |
| KR20080060226A (ko) | 2008-07-01 |
| AU2006310577B2 (en) | 2012-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR10730A (es) | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 | |
| HN2008001720A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina | |
| CL2007002018A1 (es) | Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular. | |
| CL2009001099A1 (es) | Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune. | |
| CL2007002017A1 (es) | Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple. | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| AR059390A1 (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos | |
| PA8772101A1 (es) | Imidazol-triazolopirimidinas sustituidas | |
| PA8637301A1 (es) | Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa | |
| CL2016002589A1 (es) | Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348). | |
| CR10347A (es) | Anticuerpos contra el peptidob-amiloide | |
| CL2007003520A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. | |
| CL2007002641A1 (es) | Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias. | |
| CL2008000691A1 (es) | Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades. | |
| CL2007003756A1 (es) | Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. | |
| SV2009003299A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa | |
| CL2007000161A1 (es) | Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
| EA201100297A1 (ru) | Биотесты на белок polyq | |
| CR10099A (es) | Inmunoglobulinas dirigidas contra nogo | |
| CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
| CR10165A (es) | "uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento de depresión" | |
| CL2007002511A1 (es) | Compuestos derivados de pirrolo[2,3-f]isoquinolina, inhibidores de cinasa-2; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune. | |
| AR058173A1 (es) | Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas | |
| PA8806501A1 (es) | Triazolotriazinas y triazolopirazinas y su uso | |
| HN2006029142A (es) | Proceso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |